title: MicroRNA-29b mediates altered innate immune development in acute leukemia.
abstract: Natural killer (NK) cells can have potent antileukemic activity following haplo-mismatched, T cell-depleted stem cell transplantations for the treatment of acute myeloid leukemia (AML), but they are not successful in eradicating de novo AML. Here, we have used a mouse model of de novo AML to elucidate the mechanisms by which AML evades NK cell surveillance. NK cells in leukemic mice displayed a marked reduction in the cytolytic granules perforin and granzyme B. Further, as AML progressed, we noted the selective loss of an immature subset of NK cells in leukemic mice and in AML patients. This absence was not due to elimination by cell death or selective reduction in proliferation, but rather to the result of a block in NK cell differentiation. Indeed, NK cells from leukemic mice and humans with AML showed lower levels of TBET and EOMES, transcription factors that are critical for terminal NK cell differentiation. Further, the microRNA miR-29b, a regulator of T-bet and EOMES, was elevated in leukemic NK cells. Finally, deletion of miR-29b in NK cells reversed the depletion of this NK cell subset in leukemic mice. These results indicate that leukemic evasion of NK cell surveillance occurs through miR-mediated dysregulation of lymphocyte development, representing an additional mechanism of immune escape in cancer.
authors: Bethany L
authors: BL
authors: Mundy-Bosse
authors: Steven D
authors: SD
authors: Scoville
authors: Li
authors: L
authors: Chen
authors: Kathleen
authors: K
authors: McConnell
authors: Hsiaoyin C
authors: HC
authors: Mao
authors: Elshafa H
authors: EH
authors: Ahmed
authors: Nicholas
authors: N
authors: Zorko
authors: Sophia
authors: S
authors: Harvey
authors: Jordan
authors: J
authors: Cole
authors: Xiaoli
authors: X
authors: Zhang
authors: Stefan
authors: S
authors: Costinean
authors: Carlo M
authors: CM
authors: Croce
authors: Karilyn
authors: K
authors: Larkin
authors: John C
authors: JC
authors: Byrd
authors: Sumithira
authors: S
authors: Vasu
authors: William
authors: W
authors: Blum
authors: Jianhua
authors: J
authors: Yu
authors: Aharon G
authors: AG
authors: Freud
authors: Michael A
authors: MA
authors: Caligiuri
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D053804:Granzymes / Q000235:genetics / Q000276:immunology; D006801:Humans; D007113:Immunity, Innate; D007694:Killer Cells, Natural / Q000276:immunology* / Q000473:pathology; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D051379:Mice; D008822:Mice, Transgenic; D035683:MicroRNAs / Q000235:genetics / Q000276:immunology*; D009363:Neoplasm Proteins / Q000235:genetics / Q000276:immunology; D054353:Perforin / Q000235:genetics / Q000276:immunology; D012334:RNA, Neoplasm / Q000235:genetics / Q000276:immunology*; D020825:T-Box Domain Proteins / Q000235:genetics / Q000276:immunology; D019139:Tumor Escape; D000098815:T-bet Transcription Factor
chemical_list: C491199:EOMES protein, human; C491198:Eomes protein, mouse; C547014:MIRN29 microRNA, mouse; C532045:MIRN29a microRNA, human; D035683:MicroRNAs; D009363:Neoplasm Proteins; D012334:RNA, Neoplasm; D020825:T-Box Domain Proteins; D000098815:T-bet Transcription Factor; D054353:Perforin; D053804:Granzymes; C509214:Gzmb protein, mouse